newsfilter
← Earnings
Earnings Releases·

Verrica Pharmaceuticals — Third Quarter 2026 Earnings Summary

Verrica Pharmaceuticals reported third-quarter 2026 total revenue of $6.9 million, driven by a record $5.7 million in net product revenue from YCANTH, which represents an 11.9% increase over the previous quarter. The company completed enrollment in its first pivotal Phase 3 trial for common warts and achieved milestones to unlock an additional $15.0 million in non-dilutive growth capital, extending its cash runway into the fourth quarter of 2027. Additionally, Verrica announced it is exploring the development of its oncolytic peptide, VP-315, for the treatment of Gorlin syndrome, a rare genetic disease characterized by frequent basal cell carcinomas.

Company
VERRICA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology